Cellular Senescence in Liver Cancer: How Dying Cells Become "Zombie" Enemies.
Aurora GazzilloCamilla VolponiCristiana SoldaniMichela Anna PolidoroBarbara FranceschiniAna LleoEduardo BonavitaMatteo DonadonPublished in: Biomedicines (2023)
Liver cancer represents the fourth leading cause of cancer-associated death worldwide. The heterogeneity of its tumor microenvironment (TME) is a major contributing factor of metastasis, relapse, and drug resistance. Regrettably, late diagnosis makes most liver cancer patients ineligible for surgery, and the frequent failure of non-surgical therapeutic options orientates clinical research to the investigation of new drugs. In this context, cellular senescence has been recently shown to play a pivotal role in the progression of chronic inflammatory liver diseases, ultimately leading to cancer. Moreover, the stem-like state triggered by senescence has been associated with the emergence of drug-resistant, aggressive tumor clones. In recent years, an increasing number of studies have emerged to investigate senescence-associated hepatocarcinogenesis and its derived therapies, leading to promising results. In this review, we intend to provide an overview of the recent evidence that unveils the role of cellular senescence in the most frequent forms of primary and metastatic liver cancer, focusing on the involvement of this mechanism in therapy resistance.
Keyphrases
- drug resistant
- dna damage
- endothelial cells
- stress induced
- multidrug resistant
- squamous cell carcinoma
- acinetobacter baumannii
- small cell lung cancer
- palliative care
- oxidative stress
- stem cells
- single cell
- mesenchymal stem cells
- papillary thyroid
- atrial fibrillation
- signaling pathway
- coronary artery bypass
- percutaneous coronary intervention
- drug induced
- lymph node metastasis